Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 116

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 116
---
 set forth in the Divestiture Agreement, and Aadi is subject to certain indemnification obligations with respect to such representations, warranties, covenants and agreements. In addition, you should not rely on the covenants and agreements in the Divestiture Agreement as actual limitations on the respective businesses of Aadi, Aadi Sub or Kaken because the parties may take certain actions that are either expressly permitted in the confidential disclosure letter to the Divestiture Agreement or as otherwise consented to by the appropriate party, which consent may be given without notice to the public (prior or otherwise). The Divestiture Agreement is described below, and included as Annex A, only to provide you with information regarding its terms and conditions, and not to provide you with any other factual information regarding Aadi, Aadi Sub, Kaken or their respective businesses. Accordingly, the representations, warranties, covenants and other agreements in the Divestiture Agreement should not be read alone, and you should read the information provided elsewhere in this document and in our filings with the SEC regarding Aadi, Aadi Sub and their respective businesses.

Closing and Effect of the Divestiture

The Divestiture Agreement provides that the completion of the Divestiture will take place (1) on a date to be agreed upon by Kaken and Aadi that is no
later than the second business day after the last condition to be satisfied or waived of the conditions to closing set forth in the Divestiture Agreement is satisfied or waived (excluding conditions that by their terms are to be satisfied as the
closing, but subject to the satisfaction or waiver of each of such conditions); or (2) at such other time agreed to in writing by Aadi and Kaken.

- 73 -

The Divestiture Agreement provides that, on the terms and subject to the conditions of the Divestiture Agreement, at the closing, Aadi will sell, assign, transfer, convey and deliver all of the issued and outstanding shares of Aadi Sub to Kaken, and Kaken will purchase all of the issued and outstanding shares of Aadi Sub from Aadi. Purchase Price Adjustments The purchase price of $100 million cash payment is subject to adjustment as follows:

| • |     | an adjustment for cash of Aadi Sub as of the completion of the Divestiture, pursuant to which the amount of cash                                                                                                                           
 will be equal to the difference of (1) the aggregate amount of all cash and cash equivalents (other than restricted cash) of Aadi Sub